NCT03580824View on ClinicalTrials.gov

A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and Infants

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

June 14, 2022

Study Completion Date

June 14, 2022

Conditions
Malaria,Falciparum
Interventions
BIOLOGICAL

R21 in Matrix- M adjuvant vaccine

R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.

Trial Locations (1)

PO Box 230, 80108

KEMRI/Wellcome Trust Programme, Centre for Geographic Medicine Research - Coast, Kilifi

Sponsors
All Listed Sponsors
collaborator

Kenya Medical Research Institute

OTHER

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

University of Oxford

OTHER